"As we begin 2008, new challenges have emerged, especially the initial reaction to the Enhance trial," said Chief Executive Fred Hassan. "We and our joint venture partner Merck acted with integrity and good faith with respect to that trial. We stand behind Vytorin and Zetia, behind the validity of the science, and behind our commitment to doing what's right for patients and physicians."
WSJ
But Senator Grassley has some more questions!
No comments:
Post a Comment